Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABA(A) potentiating activity for use in dementia

BACKGROUND: Synaptic dysfunction is a key event in pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD) where synapse loss pathologically correlates with cognitive decline and dementia. Although evidence suggests that aberrant protein production and aggregation are the causati...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Neurosci
Autori principali: Luo, Jia, Lee, Sue H., VandeVrede, Lawren, Qin, Zhihui, Piyankarage, Sujeewa, Tavassoli, Ehsan, Asghodom, Rezene T., Aissa, Manel Ben, Fà, Mauro, Arancio, Ottavio, Yue, Lan, Pepperberg, David R., Thatcher, Gregory R. J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2015
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4612403/
https://ncbi.nlm.nih.gov/pubmed/26480871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12868-015-0208-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi